Anti-CD26 Ligand Potency Testing With Quantitative T-Cell Cytometry
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for determining the potency of anti-CD26 monoclonal antibodies, such as begelomab, are complex and difficult to reproduce in vitro due to their multiple action mechanisms, making it challenging to quantify their biological activity effectively.
Innovation Solution
A quantitative cellular method involving incubation of human T lymphocytes with begelomab, followed by cytofluorimetric analysis to measure the internalization of the CD26 receptor and inhibition of pro-inflammatory cytokine secretion, providing a direct and reproducible potency test.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If multiple action mechanisms of anti-CD26 monoclonal antibodies are considered, then comprehensive biological activity assessment is improved, but assay complexity and reproducibility deteriorate
Solution Approach 1:
The patent segments the complex biological activity into distinct measurable components: CD26 receptor internalization and pro-inflammatory cytokine secretion inhibition. By dividing the overall biological effect into separate, quantifiable events, the assay achieves comprehensive coverage while maintaining manageable complexity through modular measurement steps.
Solution Approach 2:
The patent extracts specific measurable parameters (CD26 internalization percentage and cytokine secretion levels) from the complex biological activity profile. This extraction allows focused measurement of key functional outcomes rather than attempting to measure all biological effects simultaneously, thereby simplifying the assay while preserving quantitative accuracy.
2Ease of operation
If in vitro potency testing is simplified, then ease of operation is improved, but measurement precision and reliability deteriorate
Solution Approach 1:
The patent introduces flow cytometry as an intermediary measurement tool that bridges the gap between simple operation and reliable measurement. The flow cytometric analysis of CD26 internalization provides an objective, quantifiable readout that is both easy to perform and highly reliable for potency determination, eliminating the need for complex multi-parameter assays.
Solution Approach 2:
The patent replaces complex biochemical assays with a more straightforward flow cytometric measurement system. By substituting intricate molecular biology techniques with fluorescence-based cellular imaging and analysis, the assay achieves both operational simplicity and measurement reliability through physical/optical detection rather than complex biochemical processing.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method allows for precise quantification of begelomab's potency through CD26 internalization and cytokine inhibition, ensuring reliable quality control during development and therapeutic applications.
Implementation Method 1
incubation at 37°C of a population of human T lymphocytes expressing the CD26 receptor... with begelomab... determination of the MFI value of CD26 measured for the sample of cells treated with begelomab... evaluation of the internalization percentage of the CD26 receptor
Implementation Method 2
incubation with anti-CD26 antibody marked with fluorochrome that recognizes an epitope on the CD26 receptor... determination of the MFI value... by means of cytofluorimetric analysis
Data Source
Figure 1
Figure 2A~3A
Figure 3B~3D
AI summary
The present invention relates to a quantitative cellular method for the in vitro determination of the effect of an anti-CD26 ligand, preferably of an anti-CD26 monoclonal antibody, such as begelomab.